Occasional review: influenza in COPD: pathogenesis, prevention, and treatment.
Influenza viruses cause respiratory tract infections that in patients with underlying lung diseases such as chronic obstructive pulmonary disease (COPD) are associated with exacerbations and excess morbidity and mortality. Typically, influenza B is associated with relatively mild, local outbreaks, whereas influenza A is the cause of world-wide pandemics. Upon infection, two antigens present on the viral surface, hemagglutinin and neuraminidase result in human immunity, but since many subtypes of these antigens exist that vary over time, immunity in the population is blunted. Vaccination is advocated in high-risk groups including patients with underlying (lung) diseases and in the elderly, and needs to be repeated annually with vaccines expected to cover the expected change in viral antigenicity. When started early, antiviral drugs, especially neuraminidase-inhibitors can be prescribed in adjunct to nonspecific interventions in an attempt to shorten disease duration and to prevent complications in case of an influenza infection. Currently, the effectiveness of antiviral drugs specifically in patients with COPD has not been proven.
Wesseling
Geertjan
G
Dept of Respiratory Medicine, Maastricht University Medical Centre, Maastricht, The Netherlands. g.wesseling@lung.azm.nl
D000547:Amantadine / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D006801:Humans; D007252:Influenza Vaccines / Q000276:immunology; D007251:Influenza, Human / Q000150:complications / Q000188:drug therapy / Q000517:prevention & control*; D053139:Oseltamivir / Q000627:therapeutic use; D029424:Pulmonary Disease, Chronic Obstructive / Q000150:complications* / Q000276:immunology; D012299:Rimantadine / Q000627:therapeutic use; D053243:Zanamivir / Q000627:therapeutic use
D000998:Antiviral Agents; D007252:Influenza Vaccines; D012299:Rimantadine; D053139:Oseltamivir; D000547:Amantadine; D053243:Zanamivir